A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

Prior treatment

• Patients who had used any hypoglycemic drugs within 90 days before screening;
• Use of any drugs for weight management within 90 days prior to screening;
• Previous or planned weight loss related treatment through surgery or other weight loss means during the study period;
• History of acute pancreatitis within 180 days prior to screening;
• Clinically significant cardiovascular and cerebrovascular disease in the 6 months prior to screening;
• Participated in any other clinical trial within 3 months prior to screening;
• There is hypothyroidism at the time of screening that is not controlled with stable drug dosages;
• Have a history of major surgery within 6 months prior to screening;
• A history of drug abuse or alcohol dependence within the 6 months prior to screening;

Other illness

• Have a history of diabetes of any type;
• Personal or first-degree relatives have a personal or family history of thyroid C-cell tumor or multiple endocrine tumor syndrome type 2;
• Have a history of major depression or serious mental illness;
• Have a history of chronic pancreatitis or pancreatic surgery;
• Uncontrolled or poorly treated hypertension;
• People who are allergic to Semaglutide injection or any component of Wegovy®, or to other GLP-1 receptor agonists, or who have a pre-existing allergic disorder;
• History of malignant tumor within 5 years before screening;
• Patients with other diseases that the researchers assessed would affect the safety of the subjects, affect the efficacy evaluation or compliance, or other conditions that the researchers considered unsuitable for enrollment.

Lab values

• Laboratory tests during screening meet any of the following criteria:
  • Alanine aminotransferase (ALT)\> 2.5× upper limit of normal (ULN), aspartate aminotransferase (AST)\>2.5 ULN;
  • Estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73m2;
  • calcitonin ≥ 50 ng/L (pg/mL);
  • Triglyceride (TG) ≥500 mg/dl (5.7mmol/L);
  • Thyroid stimulating hormone (TSH) \>6 mIU/L or \<0.4 mIU/L.
• When virological tests at the time of screening show any of the following:
  • Hepatitis C virus (HCV) antibody positive, and HCV virus titer detection value exceeds the upper limit of normal value;
  • HBsAg positive and Hepatitis B virus (HBV) DNA test value exceeds the upper limit of normal value;
  • HIV positive;
  • Active syphilis: the screening period of treponema pallidum antibody positive and non-Treponema pallidum serum test (RPR or TRUST) positive;

Age

• Pregnant or lactating women or men or women of childbearing age who had a pregnancy plan during the study period (including a spouse), or who refused to take the contraceptive measures specified in the programme during the study period;

Other

• Mental Health Scale (PHQ-9) score ≥ 15 during screening;
• The subject is unable to comply with the treatment plan and diet and exercise plan established by the investigator;
• There are secondary causes affecting body weight;

• Age 18-70 years old, gender is not limited;
• Body mass index (BMI) ≥ 28 kg/m2;
• Self-report at least one unsuccessful diet and weight loss history;
• Patients must give informed consent to this study before the trial and sign the informed consent voluntarily.